USPTO serial 50075719
SANARX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- —
What this means
Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.
Need help with SANARX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Marietta, GA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Marcy L. Sperry
Marcy L. Sperry Sperry IP Law LLC dba Vivid IP3550 Lenox Road, 21st FloorAtlanta, GA 30326United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical, namely, collagen for use in the manufacture of nutritional supplements and pharmaceutical preparations | ACTIVE | — |
| 005 | Antimicrobial preparations for treating skin and wounds, namely, for preventing and treating infection and eliminating bacteria on human skin and wounds; Bone void fillers consisting of natural materials; Human allograft tissue; Pharmaceutical cleansing preparations used in the treatment of human skin and wounds, namely, preparations for preventing and treating infection, for protecting the skin, and for mechanical cleansing and removal of foreign materials; Medical cleansing preparations used in the treatment of human skin and wounds, namely, preparations for preventing and treating infection, for protecting the skin, and for mechanical cleansing and removal of foreign materials; Medical preparations for use in connection with surgical and wound care; Biological amniotic tissue intended as a soft tissue barrier and wound covering for medical purposes; Biologically derived extracellular matrix material for promoting soft tissue repair and wound healing; Non-medicated preparations consisting of hydrolyzed collagen powder and gel used for the management of wounds, ulcers, and 1st and 2nd degree burns; Allograft based biologics products, namely, an advanced cellular bone matrix for promoting bone formation, excluding wound healing and stem cell products; Biologically derived extracellular matrix material for the management of wounds; Non-medicated wound-healing preparations in the nature of powders used in the management of chronic wounds, namely, wound closure; Non-medicated wound-healing preparations in the nature of gels used in the management of chronic wounds, namely, wound closure; Orthobiologic material primarily consisting of human allograft bone and tissue; Pharmaceutical preparation, namely, collagen for wound care, dental purposes, and the treatment of arthritis; Collagen for use as a dietary supplement; Allografts, namely, human allograft tissue made from human umbilical cords; Allograft made from amniotic material; Human allograft tissue for use as wound dressings; Biologic drugs for treating inflammation and pain using regenerative tissue components; Human biological amniotic membrane tissue intended for subsequent implantation; Human biological chorionic membrane tissue intended for subsequent implantation; Topical treatment in the nature of a wound dressing for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; Topical treatment in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; Topical treatment made from chorionic material in the nature of a wound dressing for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; Topical treatment made from chorionic material in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; Wound treatment in the nature of a dressing comprising chorionic material; Wound treatment in the nature of a dressing comprising amniotic material; Wound treatment in the nature of a micronized powder comprising amniotic material for medical purposes; Topical treatment made from amniotic material in the nature of a wound dressing for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; Topical treatment made from amniotic material in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; Absorbent collagen matrix of Type I and Type III bovine collagen used in the treatment of wounds; Collagen for medical purposes, namely, bovine collagen powder for surgical wound care | ACTIVE | — |
| 010 | Synthetic bone grafts; Medical device, namely, a device for applying collagen powder to surgical wounds | ACTIVE | — |
| 037 | Cleaning, disinfection, and drying of human biological membrane tissue intended for subsequent hydration and surgical implantation | ACTIVE | — |
| 042 | Research and development of treatments for skin care, wound care, and surgical care; Development of medical preparations for use in connection with surgical and wound care | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MiMedx Group, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 037
- Other trademarks in Class 042
- Similar marks named SANARX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 27, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 27, 2026 | NWAP | NEW APPLICATION ENTERED | — |